Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.

Published byRalph Foster Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus."— Presentation transcript:

1 Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus MORT copy number. DNA methylation of the MORT promoter in receptor negative and receptor positive tumors estrogen receptor (ER) (B), progesterone receptor (PR) (C), and human epidermal growth factor receptor 2 (HER2) (D). (E) DNA methylation of the MORT promoter in triple negative (TN) tumors, tumors positive for at least one receptor and a group of normal samples (p-value is for contrast TN vs. receptor (+) tumors). (F) DNA methylation of the MORT promoter in breast tumors classified into subtypes according to PAM50 (p-values are for contrast of individual tumor subtypes vs. normal). (G) DNA methylation of the MORT promoter in samples from patients >60 years of age compared to those from patients ≤60. (H) Association between amplification of the cyclin D1 locus and DNA methylation of the MORT promoter. (I) DNA methylation of the MORT promoter in samples with wild type TP53 compared to samples with mutated TP53. (J) DNA methylation of the MORT promoter in samples with wild type GATA3 compared to samples with mutated GATA3. RPKM=reads per kilobase per million; CN=copy number; WT=wild type. Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus MORT copy number. DNA methylation of the MORT promoter in receptor negative and receptor positive tumors estrogen receptor (ER) (B), progesterone receptor (PR) (C), and human epidermal growth… J Breast Cancer Jun;20(2):

Download ppt "Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus."

Similar presentations

Triple-Negative Breast Cancer

Triple-Negative Breast Cancer
Results grade1 grade2 grade3 (1) Can we identify metabolites or metabolic pathways that are associated with breast cancer clinical parameters? Alex-CIS-GCTOF.

Results grade1 grade2 grade3 (1) Can we identify metabolites or metabolic pathways that are associated with breast cancer clinical parameters? Alex-CIS-GCTOF.
FUNCTIONAL GENOMICS REVEAL THAT THE SERINE SYNTHESIS PATHWAY IS ESSENTIAL IN BREAST CANCER Introduction: Tim Butler Spellman Lab.

FUNCTIONAL GENOMICS REVEAL THAT THE SERINE SYNTHESIS PATHWAY IS ESSENTIAL IN BREAST CANCER Introduction: Tim Butler Spellman Lab.
Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets.

Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets.
Epigenetic Control of Tamoxifen Resistant Breast Cancer Kristin Williams Arcaro Lab Thesis Resarch June 25, 2012 Kristin Williams Arcaro Lab Thesis Resarch.

Epigenetic Control of Tamoxifen Resistant Breast Cancer Kristin Williams Arcaro Lab Thesis Resarch June 25, 2012 Kristin Williams Arcaro Lab Thesis Resarch.
GeneGroupAnalysis 1.0.0-BetaCS Alejandro Quiroz-Zárate John Quackenbush lab

GeneGroupAnalysis BetaCS Alejandro Quiroz-Zárate John Quackenbush lab
Breast Cancer: BRCA1/2 Erin Hayes Foundations of Medicine Blue Valley CAPS October 28, 2015 1.

Breast Cancer: BRCA1/2 Erin Hayes Foundations of Medicine Blue Valley CAPS October 28,
Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.
IN CANCER MOLECULAR DETECTION. WHAT DO THEY DETECT? Specific proteins Expression of certain genes Mutations Epigenetic Changes.

IN CANCER MOLECULAR DETECTION. WHAT DO THEY DETECT? Specific proteins Expression of certain genes Mutations Epigenetic Changes.
Triple negative (TN) vs. positive (TP) breast cancer (BC) analysis with public genomic data yields AGR3 as a biomarker Anita Umesh, Jenny Park, James Shima,

Triple negative (TN) vs. positive (TP) breast cancer (BC) analysis with public genomic data yields AGR3 as a biomarker Anita Umesh, Jenny Park, James Shima,
Cancer. Cancer is a disease of the cell cycle Caused by one or more of the following: Increase in growth signals Loss of inhibitory signals In addition,

Cancer. Cancer is a disease of the cell cycle Caused by one or more of the following: Increase in growth signals Loss of inhibitory signals In addition,
Supplementary Figure 1. Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer. (A-C) CDK7, CyclinH and MAT1 mRNA levels, determined by real-time.

Supplementary Figure 1. Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer. (A-C) CDK7, CyclinH and MAT1 mRNA levels, determined by real-time.
Supplementary Table 1. A)Patient details for Fresh Frozen test cohort, B) Patient details for validation cohort Age Median64 Range41-89 Grade 13 214 310.

Supplementary Table 1. A)Patient details for Fresh Frozen test cohort, B) Patient details for validation cohort Age Median64 Range41-89 Grade
THE GENETIC BASIS OF CANCER

THE GENETIC BASIS OF CANCER
Number of brain metastasis

Number of brain metastasis
Figure 1. Correlation between estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression in primary breast tumors and synchronous axillary.

Figure 1. Correlation between estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression in primary breast tumors and synchronous axillary.
Figure 1 The heterogenous landscape of triple-negative breast cancer

Figure 1 The heterogenous landscape of triple-negative breast cancer
TRIPLE NEGATIVE BREAST CANCER (TNBC) & ETHNIC MINORITIES

TRIPLE NEGATIVE BREAST CANCER (TNBC) & ETHNIC MINORITIES
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive.

Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive.

Similar presentations

Ads by Google